 SAN DIEGO, CA ACCESSWIRE March 24, 2021 Nascent Biotech, Inc. OTCQB:NBIO Nascent Biotech, Nascent, or the Company, a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab PTB, the Companys lead Monoclonal Antibody Mab therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. Screening to enroll patients in the trial is already underway. 